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Objectives. Statin drugs act as inhibitors of the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme early in
the mevalonate pathway, thereby reducing the endogenous cholesterol synthesis. In recent studies, it has been suggested from
epidemiological data that statins also may improve vitamin D status, as measured by increased plasma 25-hydroxyvitamin D
(25OHD) levels. We now report the results from a randomised controlled trial on eﬀects of simvastatin on plasma 25OHD
levels. Design and Methods. We randomised 82 healthy postmenopausal women to one year of treatment with either simvastatin
40mg/d or placebo and performed measurement at baseline and after 26 and 52 weeks of treatment. The study was completed
by 77 subjects. Results. Compared with placebo, plasma levels of cholesterol and low-density lipoproteins decreased in response
to treatment with simvastatin, but our study showed no eﬀect of simvastatin on vitamin D status. However, plasma levels of
triglycerides were inversely associated with tertiles of plasma 25OHD levels and changes in plasma triglycerides levels correlated
inversely with seasonal changes in vitamin D status. Conclusion. Our data do not support a pharmacological eﬀect of statins on
vitamin D status, but do suggest that vitamin D may inﬂuence plasma lipid proﬁle and thus be of importance to cardiovascular
health.
1.Introduction
During recent years, treatment with statins has been sug-
gestedtocausepositiveeﬀectsonbone.Although,discrepant
results have been reported in clinical studies on eﬀects of
statins on bone mineral density (BMD) and bone turnover
[1–5], several epidemiological studies have shown that treat-
ment with statins is associated with a reduced risk of fracture
[6–10]. Several mechanisms of action of statins on bone have
been suggested. Statins may exert a bone anabolic action due
toanincreasedosteoblasticsynthesisofbonemorphogenetic
protein 2 (BMP-2), a growth factor that causes osteoblastic
proliferation [11], as well as antiresorptive eﬀects similar
to nitrogen-containing bisphosphonates (amino-BP) [12].
Moreover, an eﬀect of statins on vitamin D metabolism has
been suggested as an additional mechanism of action by
whichstatins may exert pleiotropic eﬀects.Inseveral[13–16]
but not all [17–19] studies, treatment with statins has been
associated with an improved vitamin D status. An emerging
amount of evidence suggests that an impaired vitamin D
status increases the risk of diﬀerent types of cancers and
chronic disorders, including cardiovascular diseases [20, 21].
If statins improve vitamin D status this could be a plausible
explanation for the ﬁndings of not only a decreased fracture
risk, but also a decreased risk of malignant diseases in users
of statin drugs [22]. Thus, in a randomised controlled design
we studied eﬀects of one year of simvastatin treatment on
vitamin D status in a group of healthy postmenopausal
women.
2.SubjectsandMethods
In year 2000, we initiated a study on eﬀects of statin
treatment on bone. The design and major results of the2 International Journal of Endocrinology
study has previously been detailed [1]. In brief, in a double-
blinded design we randomised 82 healthy Caucasian women
to one year of treatment with either simvastatin 40mg/d
or placebo. In addition, all studied subjects received a
daily supplement with 400mg of elementary calcium, but
no vitamin D supplementations. Calcium and simvastatin
tablets were obtained commercially.
We recruited studied subjects, through invitations by
letter, from a random sample of the general background
population. We only included women who were more than
12 months postmenopause and below 76 years of age. In
addition, we required studied subjects to be healthy as
assessed by a standard biochemical screening program and
to have osteopenia at the lumbar spine or total hip, that
is, a BMD less than 1 standard deviation (SD) below the
mean of peak bone mass (T-score < −1). We excluded
women with diseases or use of drugs known to aﬀect calcium
homeostasis and bone metabolism, including impaired renal
(plasma creatinine >120μmol/L) or hepatic (plasma alanine
aminotransferase >80U/L) function, and alcohol abuse of
more than 14 units a week within the last 2 years. None
of studied subjects had known hyperlipidemia prior to
study start. As a safety measure, we excluded subjects with
low plasma cholesterol levels (total cholesterol <4.0mmol/L
and/or LDL <2.5mmol/L).
The study was carried out in accordance with the
Declaration of Helsinki II. It was approved by the regional
Ethical Committee (Aarhus County # 2000/0223) and the
Danish National Board of Health. Each individual gave
verbal and written informed consent prior to the study. The
GoodClinicalPractice(GCP)UnitattheUniversityHospital
of Aarhus, Denmark, monitored the study.
3. Biochemistry
During trial, blood samples were drawn between 7.00
a.m. and 10.30 a.m. after an overnight fast. At time of
study, we analysed plasma levels of calcium, creatinine,
albumin, total cholesterol (TC), LDL cholesterol (LDL),
HDL cholesterol (HDL), and triglyceride (TG) by standard
laboratorymethods.Wenowreportmeasurementsofplasma
25-hydroxyvitamin D (P-25OHD) levels in samples collected
at baseline and after 6 and 12 months of treatment. Since
collected, all samples have been stored at −80
◦C. We
analysed P-25OHD levels using an isotope dilution liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
method adapted from Maunsell et al. [23]. Mean coeﬃcients
ofvariationfor25OHD3were6.4%and9.1%atlevelsof66.5
and 21.1nmol/L and for 25OHD2 the CV values were 8.8%
and 9.4% at levels of 41.2 and 25.3nmol/L.
4. Statistics
We assessed diﬀerences between study groups using Chi-
square tests for categorical variables and a two-sample
t-test or Mann-Whitney U-test for continuous variables,
as appropriate. For this analysis, we had stored samples
for 77 study subjects who completed the one year of
treatment (38 in the placebo group and 39 in the statin
group). Accordingly, data are presented as a per-protocol
analysis. Serial changes were studied using analysis of vari-
ance (ANOVA) for repeated measurements (RM-ANOVA),
with treatment group as the independent variable (eﬀect
of time by group). Assumptions for repeated measures
ANOVA were checked by Mauchly’s test of sphericity, and
accordingly adjustment in the degrees of freedom was made
(Huynh-Feldt epsilon). In case of a signiﬁcant between-
groups diﬀerence by repeated measures ANOVA, diﬀerences
between groups were analysed at each time point of mea-
surements by a posterior analysis using a two-sample test.
We assessed association between studied parameters using
correlations and multiple regression analyses. All results
are given as mean ± standard error of the mean (SEM)
unless otherwise stated. Statistical analysis was performed
using Statistical Package for Social Sciences (SPSSs 14.0) for
Windows.
5. Results
Women included in the study had a median age of 64 years
(range 53 to 74 years). Baseline characteristics including P-
25OHD levels did not diﬀer statistically between groups,
except that women randomised to placebo by change were
heavier than subjects randomised to simvastatin treatment
(Table 1). Only three of our studied subjects had vitamin
D deﬁciency deﬁned as a P-25OHD level <25nmol/L,
whereas 11 (14%) had vitamin D insuﬃciency (P-25OHD
<50nmol/L). One third of our studied subjects had a P-
25OHD level >80nmol/L (Table 1). As previously reported,
52 weeks of treatment with simvastatin caused, compared
with placebo, a signiﬁcant decrease in plasma levels of
cholesterol (−27%, 95% conﬁdence interval (CI), −22% to
−32%, P <. 001) and LDL-cholesterol (−45%, 95% CI,
−38% to −52%, P <. 001), whereas plasma levels of HDL-
cholesterol and triglycerides did not change signiﬁcantly
in response to treatment [1]. Similarly, statin treatment
did not aﬀect plasma levels of parathyroid hormone or
biochemical markers of bone turnover, including plasma
levels of C-terminal telopeptide of type I (CTX), colla-
gen osteocalcin, and bone speciﬁc alkaline phosphatase
[1].
5.1. Eﬀects of Simvastatin Treatment on Plasma 25OHD
Levels. Treatment with simvastatin did not aﬀect P-25OHD
levels compared with placebo (P = .53 by RM-ANOVA,
Figure 1). P-25OHD levels did not change signiﬁcantly
between baseline and week 52 within the group of women
treated with simvastatin (P = .40 by paired sample test)
or placebo (P = .90). As shown in Figure 1, P-25OHD
levels were higher in both study groups at week 26 compared
with values at baseline and week 52, which is attributable
to seasonal variations. Samples at baseline and week 52
werecollectedduringwintertime(OctobertoApril),whereas
samplesatweek26werecollectedduringsummertime(April
to October).International Journal of Endocrinology 3
Table 1: Baseline characteristics by study group (mean ± sem).
Placebo (n = 38) Simvastatin (n = 39) P-value (n = 77)
Age (years)(1) 64 (53–72) 63 (53–72) .70
Years postmenopausal(1) 18 (6–44) 19 (7–31) .80
Scale body weight (kg) 69.6 ±1.46 4 .6 ±1.8. 0 4
Body mass index (kg/m2)2 6 .4 ±0.52 4 .7 ±0.7. 0 4
Biochemestry
Plasma
Calcium (adj.) (mmol/L) 2.44 ±0.01 2.46 ±0.01 .17
Creatinine (mol/L) 77±27 8 ±2. 8 2
Total cholesterol (mmol/L) 6.4 ±0.16 .5 ±0.2. 6 9
HDL cholesterol (mmol/L) 1.8 ±0.12 .0 ±0.1. 1 4
LDL cholesterol (mmol/L) 4.0 ±0.14 .0 ±0.2. 9 9
Triglycerides (mmol/L) 1.3 ±0.11 .1 ±0.1. 0 8
P-PTH (pmol/L) 4.2 ±0.24 .4 ±0.2. 3 9
25OHD (nmol/L) 70 ±47 1 ±4. 8 9
25OHD <25nmol/L, N (%) 2 (5%) 1 (3%) .54
25OHD <50nmol/L, N (%) 7 (18%) 4 (10%) .35
25OHD <80nmol/L, N (%) 25 (66%) 26 (67%) .94
(1)Median (range).
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Figure 1: Changes in plasma 25-hydroxyvitamin D (P-25OHD)
levels by treatment group (mean ± SEM).
5.2. Associations between Vitamin D- and Cholesterol-Status.
In order to assess whether P-25OHD levels inﬂuence choles-
terolstatus,weanalysedbaselineindicesofcholesterolstatus,
as measured by plasma levels of TC, LDL, HDL, or TG by
tertiles of P-25OHD levels (Table 2). Women in the highest
tertile of P-25OHD levels (>80nmol/L) had signiﬁcantly
(P <. 01) lower plasma levels of TG than those in the lowest
P-25OHD tertile, whereas plasma HDL levels increased bor-
derline signiﬁcantly by P-25OHD tertiles (Table 2). Dividing
studied subjects into groups pf vitamin D status according
to the often used cutoﬀ limits for vitamin D status,
that is, P-25OHD <50, between 50–80, and >80nmol/L
showed very similar results with signiﬁcantly lower TG levels
(1.0 ± 0.5mmol/L) in vitamin D replete women (P-25OHD
>80nmol/L) than in women with vitamin D insuﬃciency
(P-25OHD <50nmol/L: TG 1.3 ± 0.5mmol/L, P = .03).
Moreover, on averages, P-25OHD levels increased from 71 ±
25nmol/L at wintertime (baseline) to 80 ± 25nmol/L at
summertime (week 26). Concomitantly, plasma TG levels
decreased from 1.2 ± 0.5mmol/L to 1.1 ± 0.5mmol/L. In a
linear regression analysis, adjusted for treatment allocation,
the seasonal changes in P-25OHD levels were signiﬁcantly
associated with the concomitant changes in plasma TG levels
(β =− 0.150, r = 0.47, P <. 01). Similarly, the decrease
in P-25OHD levels between week 26 and 52 (from summer-
towinter-time)correlatedsigniﬁcantlywiththeconcomitant
changes in plasma TG levels (β =− 0.189, r = 0.36, P <. 01).
Further adjustments for BMI did not change the results.
6. Discussion
In a randomised, controlled study, we found no eﬀects
on plasma 25OHD levels of one year of treatment with
simvastatin 40mg/d compared with placebo. However, our
analysisshowedaneﬀectofvitaminDstatusonplasmalevels
of TG, a ﬁnding that may contribute to our understanding of
the potential positive eﬀects of vitamin D on cardiovascular
health.
For more than two decades, statins have been used
to reduce cholesterol levels in patients with cardiovascular
diseases.TheyactasHMG-CoAreductaseinhibitors,thereby
reducing the endogenous cholesterol synthesis. When statins
were introduced, it was a matter of concern whether inhibi-
tion of the cholesterol biosynthetic pathway may aﬀect other4 International Journal of Endocrinology
Table 2: Indices of cholesterol status by tertiles of plasma 25-hydroxyvitamin D (P-25OHD) levels at baseline (mean ± SD).
P-total cholesterol P-HDL cholesterol P-LDL cholesterol P-triglycerides
(mmol/L) (mmol/L) (mmol/L) (mmol/L)
Tertile of P-25OHD levels
(1) (<58nmol/L) 6.4 ±1.11 .7 ±0.44 .4 ±1.01 .3 ±0.6
(2) (58–80nmol/L) 6.6 ±0.82 .0 ±0.64 .1 ±0.81 .3 ±0.5
(3) (>80nmol/L) 6.6 ±1.12 .0 ±0.5
∗ 4.1 ±1.01 .0 ±0.5
∗
p-trend 0.52 0.06 0.98 <0.01
∗P<. 05 compared with lowest tertile by post-hoc test.
metabolic processes which are dependent on intermediates
from this pathway. Especially, concerns have been paid to the
reduced tissue concentrations of 7-dehydrocholesterol (7-
DHC) in response to treatment with statins. As 7-DHC is the
precursor for endogenous skin synthesis of cholecalciferol,
reduced levels of 7-DHC may impair vitamin D status.
However, in a study including 17 men and women on
treatment with pravastatin and 14 hypercholesterolemic age
and gender matched controls, vitamin D levels increased in
a similar manner in both groups in response to exposure
of the skin surface to type B ultraviolet (UV-B) radia-
tion, indicating no harmful eﬀects of pravastatin on the
endogenous vitamin D synthesis [19]. On the contrary, in
several papers statin therapy has been suggested to improve
vitamin D status. In a group of 83 Spanish men and women
with acute coronary syndrome in whom treatment with
atorvastatin was initiated, vitamin D status as measured
by P-25OHD levels improved. Thus, during one year of
observation P-25OHD levels increased from 41 ± 19nmol/L
at baseline to 47 ± 19nmol/L after 12 months, which,
according to the investigators, was attributable to treatment
with atorvastatin [24]. Similar results have been reported
by other investigators [15, 16], including a cross-sectional
analysis showing increased P-25OHD levels in patients on
treatment with statins [14]. In contrast to these ﬁndings
from observational studies, the results from our randomised
controlled study showed no eﬀect of simvastatin treatment
on P-25OHD levels. Although we cannot exclude diﬀerential
eﬀects on vitamin D status of diﬀerent types of statin drugs
(e.g., atorvastatin versus simvastatin), we ﬁnd it most likely
that the ﬁndings from the uncontrolled studies are due to
unmeasured changes in indices aﬀecting P-25OHD levels.
In general, P-25OHD levels are determined by intake from
food items rich in vitamin D (especially fatty ﬁsh), use of
vitamin D supplements, and sun exposure. To the best of our
knowledge, none of these indices was controlled for in the
hitherto published uncontrolled studies on possible eﬀects
of statins on vitamin D status. Most likely, the ﬁndings from
these studies are due to the coincidence of changes in life-
style habits in relation to administration of statin drugs.
Vitamin D has, however, independently of treatment
with statins, been implicated in cardiovascular health and
atherogenesis [25]. Results from a randomised controlled
study showed a decreased blood pressure in response to
UVB exposure [26], and P-25OHD levels have been shown
to correlate inversely with risk of atherosclerosis in several
cohort studies [21, 27, 28]. However, other investigators
have reported either no eﬀects or even detrimental eﬀects
on plasma lipid levels in response to administration of
vitamin D [29–32]. The vitamin D receptor is expressed by
both cardiac myocytes, endothelial-, and smooth vascular
muscle-cells and these cells also express the 1 α-hydroxylase
enzyme, that is, they may locally activate vitamin D from its
circulationprecursor(25OHD)toitsactivemetabolite(1,25-
dihydroxyvitamin D) [33, 34]. Several mechanisms of action
have been implicated in the potential antiatherosclerotic
eﬀectsofvitaminD,includingadownregulationoftherenin-
angiotensin system, and a reduced expression of mRNA and
protein levels of plasminogen activator inhibitor-1 (PAI-
1) and thrombospondin-1 (THBS1) which are known to
be involved in the development of atherosclerosis [35, 36].
In addition, our data points toward a further mechanism
by which vitamin D may protect against cardiovascular
diseases, that is, through decreased TG levels [37]. A possible
mechanism of action by which vitamin D lowers TG levels
is through an increased activity of the lipoprotein lipase,
which has been shown to be regulated by vitamin D in
adipocytes [38]. Our data on eﬀects of vitamin D on TG
levels are limited by the cross-sectional design of the analysis
and included only women. Further randomised controlled
studies on eﬀects of vitamin D on plasma lipid proﬁle are
warranted, including studies in men.
In conclusion, results from our randomised, controlled
trial do not support an eﬀect of statin treatment on vitamin
D status as determined by measurement of plasma 25OHD
levels. However, P-25OHD levels may improve the plasma
lipid proﬁle and thereby risk of cardiovascular disease.
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